5-Chloro-6-methylnicotinic acid, 95%, 250mg

(2R,5R)-5-benzyl-3-methyl-2-(5-methylfuran-2-yl)imidazolidin-4-one, 97%, 250mg

1-(4-Aminophenyl)cyclopropanecarbonitrile, 97.0%, 100mg

2-(2-Aminoéthylamino)éthanol, min 98%, pour synthèse, 1 L, emballage verre

(S)-2-Methyl-pyrrolidine hydrochloride, 95.0%, 10g

2-(Benzyloxy)-4-iodophenol, 98%, 1g

Methyl 5-chlorobenzofuran-2-carboxylate, 95+%, 1g

3-(4-nitrophenyl)-1,2,4-oxadiazole, 5g

2,4-Difluoro-alpha,alpha-1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol, 97.0%, 5g

Methyl 5-fluoro-1H-indole-3-carboxylate, 95.0%, 1g

2-Methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile, 95.0%, 1g

2-(ALLYL(BENZYL)AMINO)ACETONITRILE, 95.0%, 100mg

4-Piperidinecarboxamide, 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, 98%, 1g